[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Semmelweis University Heart and Vascular Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":130},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,52,78,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100615773","oral-microbiome-in-carotid-atherosclerosis-100615773",false,"NCT07296965","Oral Microbiome in Carotid Atherosclerosis","The Role of the Oral Microbiome in Carotid Atherosclerosis: Investigating in a Cross-sectional Study the Microbial Influence on Plaque Development and Vulnerability Based on Biobank Data","OMICA","Inclusion Criteria:\n\n* Confirmed internal carotid artery (ICA) stenosis on preoperative photon-counting computed tomography (CTA)\n* Adults (≥18 years) undergoing carotid endarterectomy at Semmelweis University.\n* Eligible for surgery based on standard anesthesiologic evaluation.\n* Willing and able to provide written informed consent for participation and sample collection.\n\nExclusion Criteria:\n\n* Active systemic infection or current antibiotic therapy within 30 days before surgery.\n* Immunosuppressive therapy or immunodeficiency disorders.\n* Inability to undergo MRI (e.g., pacemaker, metallic implants, severe claustrophobia).\n* Pregnancy or lactation.\n* Malignancy under active treatment.\n* Prior carotid surgery or stenting on the same side.\n* Refusal or inability to provide informed consent.","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","1 Year","OBSERVATIONAL","The goal of this observational study, called OMICA (Oral Microbiome in Carotid Atherosclerosis), is to learn how bacteria living in the mouth may influence the development and stability of plaques in the carotid arteries, which supply blood to the brain. Plaque buildup in these arteries can lead to stroke.\n\nResearchers want to understand whether certain oral bacteria are linked to plaque vulnerability, meaning a higher chance that the plaque will rupture and cause a stroke.\n\nThe study will include a cohort of adults scheduled for carotid endarterectomy at Semmelweis University. Participants will be enrolled in the Semmelweis University Carotid Biobank project.\n\nThe main questions the study aims to answer are:\n\nDo people with more severe gum disease or tooth infection have a higher number of bacteria in their carotid plaques, and are those plaques more likely to rupture?\n\nAre the bacteria found in vulnerable plaques different from those in stable plaques?\n\nAre similar bacteria found in the mouth, gut, and plaques, suggesting that bacteria may travel through the body?\n\nWhat participants will do:\n\nHave their oral health checked before surgery, including an exam of gum disease and tooth infections.\n\nProvide microbiome samples from the mouth, anus, urine, and carotid plaque (taken during surgery).\n\nHave preoperative photon-counting computed tomography (CT) performed to assess plaque stability and study eligibility.\n\nAll samples and imaging data will be analyzed to identify bacterial species and their relationship to plaque type.\n\nThe study does not involve any experimental treatment or medication. Participation adds no significant medical risk beyond standard care.\n\nResearchers will compare bacterial patterns between people with vulnerable plaques and those with stable plaques to identify microbial signatures linked to carotid plaque instability.\n\nThe results may help create future microbiome-based risk models for detecting people at higher risk of stroke or severe atherosclerosis.",[26,27,28,29,30],"Atherosclerosis Cardiovascular Disease","Atherosclerosis of Artery","Carotid Artery Plaque","Periodontitis","Carotid Artery Diseases",[32,33,34,35,36,37,38],"Oral Microbiome","Carotid Plaque","Plaque vulnerability","Atherosclerosis","Periodontal disease","Biobank study","Microbial colonization","RECRUITING","2026-04-21",{"date":42,"type":43},"2026-04-22","ACTUAL",{"date":45,"type":43},"2025-11-01",{"date":47,"type":21},"2029-11-01",{"name":49,"class":50},"Semmelweis University Heart and Vascular Center","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":51},"100626327","biventricular-or-left-bundle-branch-pacing-to-assess-the-effect-of-cardiac-resynchronization-therapy-in-patients-undergoing-transcatheter-aortic-valve-implantation-100626327","NCT07434193","Biventricular or Left Bundle Branch Pacing to Assess the Effect of Cardiac Resynchronization Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation","Biventricular or Left Bundle Branch Pacing to Assess the Effect of Cardiac Resynchronization Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation- the BUDAPEST CRT TAVI Trial","BUDAPEST-TAVI","Inclusion Criteria:\n\n* Age over 18 years\n* Successful and complication-free TAVI implantation for significant aortic stenosis\n* Signed informed consent after detailed patient information\n* New-onset LBBB wider than 130 ms after TAVI, persisting at the time of planned discharge (assessed postoperatively on or after day 5)(21)\n* Mildly reduced left ventricular systolic function on echocardiography at the planned time of discharge (at the earliest on postoperative day 5), with EF between 35% and 55%\n\nExclusion Criteria:\n\n* Pre-existing right bundle branch block, or prior pacemaker\u002FICD implantation associated with significant (\\>20%) ventricular pacing\n\n  * Progression of LBBB during hospitalization to a degree indicating pacemaker implantation (e.g., Mobitz II or third-degree AV block, alternating bundle branch block) before the planned discharge date\n  * Concomitant severe valvular disease of other valves (mitral, pulmonary, or tricuspid)\n  * Severe infection and\u002For septic state\n  * TAVI-associated stroke\n  * More than moderate paravalvular leak of the TAVI valve on postoperative echocardiography\n  * EF \\\u003C 35% or \\> 55% on echocardiography performed at the planned time of discharge\n  * GOLD stage IV COPD\n  * Chronic renal failure requiring regular dialysis\n  * Concurrent participation in another clinical trial",{"count":61,"type":21},360,"INTERVENTIONAL",[64],"NA","In this prospective, randomized, multicenter, open-label interventional clinical trial, the investigators' aim to test the effect of Cardiac Resynchronization Therapy (CRT) in cases of new-onset and persistent Left Bundle Branch Block (LBBB) occurring in the context of Transcatheter Aortic Valve Implantation (TAVI), in patients with moderately reduced left ventricular systolic function (35% \\\u003C EF \\\u003C 55%). The investigators hypothesize that in patients with persistent LBBB developing after TAVI and mildly reduced left ventricular systolic function (35% \\\u003C EF \\\u003C 55%), early postoperative CRT implantation favorably influences the process of myocardial reverse remodeling by reducing electromechanical dyssynchrony, thereby decreasing the combined endpoint of heart failure-related hospitalizations and mortality at one year.",[67],"Chronic Heart Failure",[69],"Cardiac Resynchronization Therapy","2026-02-22",{"date":72,"type":43},"2026-02-25",{"date":74,"type":43},"2025-11-19",{"date":76,"type":21},"2033-01-31",{"name":49,"class":50},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":62,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100554609","photobiomodulation-for-patients-with-advanced-heart-failure-100554609","NCT06501313","PhotobiomoduLation for pAtientS With Advanced hEart failuRe","LASER","Inclusion Criteria:\n\nAdvanced-stage HFrEF patients who were ineligible for heart transplantation Patients over 18 years of age The expected lifespan exceeds 1 year Consent form\n\nExclusion Criteria:\n\nNon-compliant patient Pregnant women Drug or alcohol abuse The patient is participating in another clinical trial",{"count":86,"type":21},70,[64],"The objective of the study is to examine the effectiveness of photobiomodulation therapy in patients with advanced-stage heart failure with reduced ejection fraction (HFrEF), who have been referred but ineligible for a heart transplantation. The primary endpoint is a 15% relative reduction in left ventricular end-systolic volume (LV ESV) as determined by echocardiography over a 12-month follow-up period. The secondary objective is to determine the change in NT-proBNP, a biomarker for heart failure, the change in heart failure symptoms based on the NYHA functional classification, the change in quality of life questionnaire (KCCQ), additional echocardiographic parameters, and the detection of changes in heart failure and fibrosis biomarkers. Additionally, the study aims to examine hospitalization due to heart failure and overall mortality.",[90,91],"Heart Failure With Reduced Ejection Fraction","Heart Failure, Systolic","NOT_YET_RECRUITING","2024-07-08",{"date":95,"type":43},"2024-07-15",{"date":97,"type":21},"2024-08-01",{"date":99,"type":21},"2026-05-01",{"name":49,"class":50},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":109,"targetDuration":111,"studyType":23,"phases":4,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100253471","national-plaque-registry-and-database-100253471","NCT02578355","National Plaque Registry and Database","OPeRA","Inclusion Criteria:\n\n* Age \\> 18 years\n* Subject providing written informed consent\n* Scheduled to undergo a clinically indicated coronary CTA\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Suspicion of acute coronary syndrome (acute myocardial infarction and unstable angina)\n* Recent prior myocardial infarction within 30 days prior to coronary CTA or between coronary CTA and ICA\n* Pregnancy or unknown pregnancy status in subject of childbearing potential\n* Subject requires an emergent procedure\n* Evidence of ongoing or active clinical instability, including acute chest pain (sudden onset), cardiogenic shock, unstable blood pressure with systolic blood pressure \\\u003C90 mmHg, and severe congestive heart failure (NYHA III or IV) or acute pulmonary edema\n* Inability to comply with study procedures","90 Years",{"count":110,"type":21},20000,"5 Years","The ultimate goal of this project is to develop a risk score to identify patients with vulnerable coronary atherosclerotic plaques, who are prone to suffer acute coronary syndrome. Early identification of vulnerable plaques may have an enormous impact on public health through primary and secondary prevention of acute myocardial infarction.\n\nInvestigators hypothesize that a risk score that incorporates non-invasive coronary CT imaging (calcium score and\u002For coronary CTA) in combination with clinical characteristics (classical risk prediction models) will improve the identification of patients who are at highest risk to suffer myocardial infarction or sudden cardiac death.\n\nThe overall goal of the OPeRA project is to develop, implement and validate a novel risk assessment tool based on image markers and clinical characteristics to identify patients who are at increased risk to suffer myocardial infarction or sudden cardiac death.",[35,114,115],"Coronary Artery Disease","Cardiovascular Disease",[35,114,115,117,118,119,120,106],"Coronary Computed Tomographic Angiography","CCTA","Myocardial Infarction","MI","2017-04-24",{"date":123,"type":43},"2017-04-25",{"date":125,"type":4},"2016-09",{"date":127,"type":21},"2030-12",{"name":49,"class":50},11,""]